Asfar S. Azmi
YOU?
Author Swipe
View article: Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma
Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma Open
Background Several KRASG12D inhibitors (KRASG12Di) are under clinical evaluation for pancreatic ductal adenocarcinoma (PDAC). However, as seen with other first generation KRAS inhibitors, resistance may limit their long-term efficacy, nece…
View article: An Update on Novel Pharmacotherapies for the Treatment of Neuroendocrine Tumors
An Update on Novel Pharmacotherapies for the Treatment of Neuroendocrine Tumors Open
Neuroendocrine tumors (NETs) are heterogeneous neoplasms with different molecular characteristics and prognosis. Although slow-growing, NETs are often diagnosed at an advanced stage. The treatment choice depends on primary site, extent, gr…
View article: Treatment of glioblastoma with tumor-specific amplitude-modulated radiofrequency electromagnetic fields
Treatment of glioblastoma with tumor-specific amplitude-modulated radiofrequency electromagnetic fields Open
This is the first report showing in vitro antitumor activity, disruption of the mitotic spindle, activation of the Mitotic Roles of Polo-like kinase pathway in GB. This is also the first report showing feasibility and clinical activ…
View article: Inhibition of <scp>CDK</scp>9 enhances <scp>AML</scp> cell death induced by combined venetoclax and azacitidine
Inhibition of <span>CDK</span>9 enhances <span>AML</span> cell death induced by combined venetoclax and azacitidine Open
Relapsed/refractory (R/R) disease is a major hurdle to long‐term survival of acute myeloid leukemia (AML) patients treated with intensive cytarabine (AraC)‐based chemotherapy. R/R AML salvage treatment with venetoclax (VEN) + azacitidine (…
View article: Multi-Omics Profiling Reveals the Interplay Between Genomic Instability and Microenvironmental Remodeling in Pancreatic Neuroendocrine Tumors
Multi-Omics Profiling Reveals the Interplay Between Genomic Instability and Microenvironmental Remodeling in Pancreatic Neuroendocrine Tumors Open
Pancreatic neuroendocrine tumors (PNETs) represent a biologically heterogeneous group of neoplasms shaped by both intrinsic genomic alterations and dynamic interactions with the tumor microenvironment (TME). Conventional analytical approac…
View article: Pharmacological advances in cannabinoid-based therapies for pancreatic cancer: preclinical efficacy of CCL-106 and its epimers
Pharmacological advances in cannabinoid-based therapies for pancreatic cancer: preclinical efficacy of CCL-106 and its epimers Open
View article: Development Of an Automated Electrical Cut-Off Mechanism for Mitigating Electrical Hazards During Flood
Development Of an Automated Electrical Cut-Off Mechanism for Mitigating Electrical Hazards During Flood Open
Electrocution during floods commonly happens when the increasing water levels make touch with active electrical sources, hence establishing a pathway for the flow of electricity. The risk is intensified if the floodwater makes contact with…
View article: ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma Open
View article: ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal Adenocarcinoma
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal Adenocarcinoma Open
Here, we evaluated in vivo antitumor activity, target engagement, selectivity, and tumor specificity of ADT-1004, an orally bioavailable prodrug of ADT-007 having highly potent and selective pan-RAS inhibitory activity. ADT-1004 strongly b…
View article: Abstract 1433 Targeting cancer associated cachexia at the nuclear pore
Abstract 1433 Targeting cancer associated cachexia at the nuclear pore Open
Cachexia or muscle wasting is common in metastatic disease and is associated with poor quality of life and is the number one cause of morbidity in patients with advanced malignancies. There are no effective treatments available for this de…
View article: Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection
Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection Open
Thymoquinone TQ, an active ingredient of Nigella Sativa, has been shown to inhibit COVID-19 symptoms in clinical trials. Thymoquinone Formulation (TQF or NP-101) is developed as a novel enteric-coated medication derivative from Nigella Sat…
View article: Association between cannabis use and clinical outcomes in patients with solid malignancies receiving immune checkpoint inhibitors
Association between cannabis use and clinical outcomes in patients with solid malignancies receiving immune checkpoint inhibitors Open
Background: Cannabis (CAN) use has risen significantly over the last few decades. CAN has potent immunosuppressive properties, which could antagonize the effect of immunotherapy (IO). The impact of CAN use on clinical cancer outcomes remai…
View article: Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor progression via the c-Myc-RCC1-Ran axis
Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor progression via the c-Myc-RCC1-Ran axis Open
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with limited therapeutic options. Here we for the first time evaluated the role of regulator of chromosome condensation 1 (RCC1) in PDAC subsistence and drug resistance.…
View article: Supplementary Table S1 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Table S1 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Table S1 shows the sequences of primers used for RT-qPCR
View article: Supplementary Fig S5 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S5 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S5 shows effects of KPT9274 and MRTX849 combinations on the proliferation of KRAS4BG12C and KRAS4BG12D MEFs
View article: Data from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Data from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
KRASG12C inhibitors, such as sotorasib and adagrasib, have revolutionized cancer treatment for patients with KRASG12C-mutant tumors. However, patients receiving these agents as monotherapy often develop drug re…
View article: Supplementary Fig S1 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S1 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S1 shows chemical structure of KPT9274
View article: Supplementary Fig S4 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S4 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S4 shows effects of KPT9274 and KRAS G12Ci combinations on the proliferation of HPAC and MIA-AMG-R cells
View article: Supplementary Fig S1 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S1 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S1 shows chemical structure of KPT9274
View article: Supplementary Fig S5 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S5 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S5 shows effects of KPT9274 and MRTX849 combinations on the proliferation of KRAS4BG12C and KRAS4BG12D MEFs
View article: Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model
Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model Open
Background The majority of pancreatic ductal adenocarcinoma (PDAC) patients experience disease progression while on treatment with gemcitabine and nanoparticle albumin‐bound (nab)‐paclitaxel (GemPac) necessitating the need for a more effec…
View article: Supplementary Fig S2 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S2 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S2 shows PAK4-KRAS synthetic lethal interaction identified using the Slorth database
View article: Supplementary Fig S2 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S2 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S2 shows PAK4-KRAS synthetic lethal interaction identified using the Slorth database
View article: Supplementary Fig S7 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S7 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S7 shows the quantification of spheroid disintegration assay data shown in Figure 3C
View article: Data from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Data from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
KRASG12C inhibitors, such as sotorasib and adagrasib, have revolutionized cancer treatment for patients with KRASG12C-mutant tumors. However, patients receiving these agents as monotherapy often develop drug re…
View article: Supplementary Fig S3 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S3 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S3 shows synergistic inhibition of NCI-H2122 cell proliferation by combinations of KPT9274 and KRAS G12C inhibitors
View article: Supplementary Table S1 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Table S1 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Table S1 shows the sequences of primers used for RT-qPCR
View article: Supplementary Fig S4 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S4 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S4 shows effects of KPT9274 and KRAS G12Ci combinations on the proliferation of HPAC and MIA-AMG-R cells
View article: Supplementary Fig S6 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S6 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S6 shows colony counts from the colony formation assay data shown in Figure 3A
View article: Supplementary Fig S6 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Supplementary Fig S6 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers Open
Suppl Fig S6 shows colony counts from the colony formation assay data shown in Figure 3A